NTRA - Natera and Alliance for Clinical Trials in Oncology announce activation of mid-stage trial in urothelial cancer
2024-04-01 08:42:12 ET
- Natera ( NASDAQ: NTRA ) and the Alliance for Clinical Trials in Oncology, part of the National Clinical Trials Network funded by the National Cancer Institute announced the launch of Alliance A032103, a randomized, phase II/III, biomarker-integrated trial.
- Alliance A032103 will utilize Signatera, Natera’s personalized and tumor-informed molecular residual disease test, to help guide personalized treatment based on molecular status in patients diagnosed with muscle-invasive urothelial cancer after radical cystectomy.
- In the Alliance A032103 trial, approximately 1,000 patients will be enrolled at more than 300 sites in North America.
- Source: Press Release